Vendor Intelligence Report: Qianmiao Peptide

Published 13 Jun 2026. 19-page investigative report on who is behind Qianmiao Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 8 Finnrick lab tests, Qianmiao Peptide’s overall pass rate is 88%: 7 pass / 1 fail. That signal is narrow. Every Finnrick result in the supplied record is Retatrutide, where identity and purity are comparatively reassuring, but the report documents a severe quantity-control outlier with major overfill. Under stricter scoring that penalizes fill variance, the rating falls, so Qianmiao is a plausible but caveated Retatrutide source only for buyers who can verify vial content rather than dose from the label.

The business-identity record is much weaker than the Retatrutide chemistry record. Qianmiao presents factory-style biotechnology claims, but the public trail shows a recent domain, redacted WHOIS, no named principals, and no verifiable facility operator. More importantly, captured page source contains a hidden telephone link that matches an unrelated Zhengzhou stainless-steel manufacturer, while reverse-IP and contact cues point into a small peptide-site network involving Semax Polypeptide and Jen Peptide Life. The report treats this as operator-network evidence, not as proven common ownership.

Public reputation signals are also uneven. Trustpilot shows a high headline score beside a sharply bimodal review pattern, with clustered May 2026 five-star reviews and a material one-star complaint block; Reddit and Trustpilot allegations focus on non-delivery, refund friction, and ghosting. The promotion scan did not find a conventional outside affiliate network, but did find vendor self-promotion on X using grey-market language. The catalog’s Botulinum listing sits in a different risk category entirely: no Finnrick testing, potency verification, sterility evidence, or cold-chain controls were verified.

Inside the full report:

  • Complete Retatrutide lab trail, methodology-divergence chart, quantity-variance discussion, and Appendix A Finnrick Laboratory Data.
  • WHOIS, DNS, hosting, WordPress-stack, and domain-timeline analysis for qianmiaopeptide.com.
  • Hidden-phone cross-reference to Sunning Steel and same-IP/operator-cue mapping for Semax Polypeptide and Jen Peptide Life.
  • Trustpilot distribution analysis, May 2026 review-cluster assessment, and Reddit fulfillment-complaint exhibit.
  • Botulinum catalog-risk review and material buyer-risk matrix.
  • Affiliate and promotion sweep covering X, web search, discount-code patterns, and stated coverage limits.

Risk assessment

  • Retatrutide quantity-control risk — high: Retatrutide is Qianmiao’s only Finnrick-tested product: 8 tests, 7 pass / 1 fail, 82.4% rating, with a documented severe overfill outlier of +63%.
  • Botulinum-toxin catalog risk — high: Qianmiao lists Botulinum, but no Finnrick testing, cold-chain controls, potency verification, or clinical-handling safeguards were verified.
  • Reputation-manipulation and fulfillment-complaint risk — medium: Trustpilot shows a bimodal 26 five-star / 12 one-star pattern with clustered May 2026 positives, alongside Reddit and Trustpilot non-delivery allegations.
  • Operator opacity and cross-business network risk — medium: WHOIS is redacted, no principals are named, and a hidden Qianmiao phone number matches Sunning Steel while sister peptide-site leads share infrastructure/contact cues.